Showing results (1-10 of 482) with videos related to

Sort By:
Pageof 49
Reproductive Biology and Endocrinology : RB&E|February 8, 2012
Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocolsCarlo Alviggi, Peter Humaidan, Diego Ezcurra
Frontiers in Endocrinology|October 5, 2020
Luteal Phase Support in IVF: Comparison Between Evidence-Based Medicine and Real-Life PracticesFederica Di Guardo, Habib Midassi, Annalisa Racca, et al.
F1000Research|February 25, 2017
The novel POSEIDON stratification of 'Low prognosis patients in Assisted Reproductive Technology' and its proposed marker of successful outcomePeter Humaidan, Carlo Alviggi, Robert Fischer, et al.
Reproductive Biology and Endocrinology : RB&E|March 10, 2025
The role of recombinant LH in ovarian stimulation: what's new?Carlo Alviggi, Luigi Vigilante, Federica Cariati, et al.
Frontiers in Endocrinology|October 2, 2019
Management Strategies for POSEIDON Groups 3 and 4Thor Haahr, Carlos Dosouto, Carlo Alviggi, et al.
Reproductive Biology and Endocrinology : RB&E|September 24, 2009
Biological versus chronological ovarian age: implications for assisted reproductive technologyCarlo Alviggi, Peter Humaidan, Colin M Howles, et al.
Reproductive Biomedicine Online|May 8, 2018
Predicting live birth for poor ovarian responders: the PROsPeR conceptPhilippe Lehert, Wai Chin, Joan Schertz, et al.
Frontiers in Endocrinology|July 30, 2019
Future Perspectives of POSEIDON Stratification for Clinical Practice and ResearchPeter Humaidan, Antonio La Marca, Carlo Alviggi, et al.
Reproductive Biomedicine Online|April 15, 2024
High-impact journal publishing: the devil is in the detail!Barbara Lawrenz, Peter Humaidan, Christophe Blockeel, et al.
Best Practice & Research. Clinical Obstetrics & Gynaecology|June 20, 2022
POSEIDON groups and their distinct reproductive outcomes: Effectiveness and cost-effectiveness insights from real-world data researchSandro C Esteves, Hakan Yarali, Lan N Vuong, et al.
Pageof 49